Impact of rotavirus vaccination on epidemiological dynamics in England and WalesArchived
The paper shows, through mathematical modelling, the impact of mass rotavirus vaccination in England and Wales.
Atkins KE, Shim E, Pitzer VE, Galvani AP. Vaccine. 2011 Nov 28. [Epub ahead of print]
In pessimistic scenarios (vaccine immunity lasting for the same duration as a natural infection) vaccination can both reduce the annual incidence of severe RVGE by over 70% and delay the epidemic by two and a half months; in cases where complete vaccine immunity lasts for at least three years, the model predicts disease elimination for any RVGE in children under five years of age.
The issue of cost-effectiveness, however, is not developed in the article, and current cost-effectiveness evaluations in literature do not support the introduction of rotavirus vaccination in England and Wales (see: Jit M et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 774 2009;27(44):6121–8).
Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Pre-Term European Infants: A Randomized Phase IIIb StudyArchived
1 Feb 2012 - Results of this study demonstrated that the RIX4414 vaccine was well tolerated and immunogenic in pre-term European infants: more than 75% of infants had seroconverted 30-83 days after dose 2.
Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in IrelandArchived
10 Oct 2011 - Rotavirus gastroenteritis in Ireland is a quite common and unpleasant illness, but severe disease is unusual and death extremely rare. Nonetheless, rotavirus generates considerable direct and indirect costs.
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialArchived
14 Sep 2011 - These article published in The Lancet provide new data for the efficacy of oral pentavalent rotavirus vaccine for prevention of severe rotavirus – related gastroenteritis in infant in developing countries